| Melanoma |
1 |
0.92 |
| Skin Cancer |
0 |
1 |
| Toxicology |
0 |
0.52 |
| Outpatient Clinic |
0 |
0.48 |
| Metastasis |
0 |
0.46 |
| Biomarker |
0 |
0.4 |
| Biologic Therapy |
0 |
0.39 |
| Distant Metastasis |
0 |
0.34 |
| Cancer |
0 |
0.32 |
| Immunotherapy |
0 |
0.32 |
| Health Care Reform |
0 |
0.31 |
| Hypothyroidism |
0 |
0.29 |
| Advanced Cancer |
0 |
0.28 |
| Resection |
0 |
0.24 |
| Tumor |
0 |
0.24 |
| Palliative Care |
0 |
0.18 |
| Adjuvant Therapy |
0 |
0.16 |
| Lymph Node |
0 |
0.16 |
| Quality of Life |
0 |
0.16 |
| Thyroid |
0 |
0.16 |
| Thyroid Disease |
0 |
0.16 |
| Adjuvant Setting |
0 |
0.08 |
| Adverse Effects |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Disease Recurrence |
0 |
0.08 |
| Europe |
0 |
0.08 |
| Food and Drug Administration (FDA) |
0 |
0.08 |
| Hormonal Therapy |
0 |
0.08 |
| Hospital |
0 |
0.08 |
| Neoadjuvant Therapy |
0 |
0.08 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.08 |
| Patient Safety |
0 |
0.08 |
| Social Media |
0 |
0.08 |
| UK Site Content |
0 |
0.08 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.05 |
| HIV Infection |
0 |
0.05 |
| Type 1 Diabetes Mellitus |
0 |
0.05 |